• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Tempus AI (TEM) A Bargain Following Its Lung Cancer Screening Study?

    Simply Wall St·10/23/2026 07:35:22
    Listen to the news

    Tempus AI (TEM) moved back into focus after presenting new data in Madrid, where its AI pre-screening panel for advanced non small cell lung cancer showed high biomarker sensitivity in a large real world study.

    Tempus AI’s latest lung cancer data was released as momentum in the share price has cooled in the short term, with the 7 day share price return down 10.29% and the 30 day share price return down 17.33%. However, the 90 day share price return is up 49.47% while the 1 year total shareholder return is down 26.68%, so recent buyers have seen strong gains while longer term holders have had a tougher ride.

    Spot opportunities around Tempus AI by scanning a curated set of 36 healthcare AI stocks, which are also working on AI driven breakthroughs in diagnostics and precision medicine.

    So is Tempus AI’s sharp swing a readout on real progress in the business, or just a reset in expectations and mood, and what does the current valuation say about that gap?

    Most Popular Narrative: 15.7% Undervalued

    Tempus AI’s most followed thesis currently pegs fair value at $75.68, which sits above the last close of $63.81 and frames the recent volatility as a potential valuation gap rather than a finished story.

    Tempus AI isn't simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect. The company generates revenue from multiple sources. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications segment sells access to its massive de-identified datasets and AI-powered tools to pharmaceutical companies, researchers, and healthcare organizations. Every new test and partnership adds more data, making its AI models more valuable and creating opportunities to cross-sell additional products and services.

    See why 31 investors see Tempus AI as 16% undervalued.

    Result: Fair Value of $75.68 (UNDERVALUED)

    Still, Tempus AI faces real pressure if its losses persist at the current scale or if high expectations for healthcare AI adoption begin to unwind.

    Find out about the key risks to this Tempus AI narrative.

    Another View: Tempus AI Looks Expensive On Sales

    The popular thesis sees Tempus AI as 15.7% undervalued at a fair value of $75.68. A simple sales based lens presents a tougher picture. The shares trade on a P/S of 8x, slightly above peers at 7.6x and well ahead of the US Life Sciences group at 4.8x.

    Our fair ratio sits higher at 8.5x. That indicates the market could still stretch the multiple if growth and execution align, yet it also implies there is less room for error if sentiment on high priced healthcare AI weakens again. Which story seems more compelling, the narrative or the sticker price?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:TEM P/S Ratio as at Oct 2026
    NasdaqGS:TEM P/S Ratio as at Oct 2026

    Next Steps

    Sentiment around Tempus AI is clearly split, with both caution and optimism in play, so move fast, scrutinize the data, and decide where you stand. To get a balanced view of the tension between the concerns and the upside that investors are watching, start by weighing the 1 key reward and 3 important warning signs.

    Looking for more ideas beyond Tempus AI?

    If you only focus on Tempus AI, you could miss other opportunities that better match your risk, income, or value goals across the market.

    • Target potential mispricing by scanning a curated set of 29 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect business strength.
    • Build a steadier income stream by reviewing a focused group of 6 dividend fortresses that aim to pair high yields with balance sheet resilience.
    • Dial down portfolio stress by zeroing in on 30 resilient stocks with low risk scores that score well on financial strength and volatility control.